Antileukemic activity of recombinant humanized M195-gelonin immunotoxin in nude mice

Leukemia

Volumn 10, Issue 2, 1996, Pages 321-326

  Xu, Y ^a   Xu, Q ^a   Rosenblum, M G ^b   Scheinberg, D A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

CD33; Gelonin; HuM195; Immunotoxin; Myeloid leukemia

Indexed keywords

ANTILEUKEMIC AGENT; CD33 ANTIGEN; GELONIN; IMMUNOTOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DEATH; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG TARGETING; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; MYELOID LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

EID: 0029878810     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Hertler AA, Frankel AE. Immunotoxins, a clinical review of their use in the treatment of malignancies J Clin Oncol 1989; 7: 1932-1942
2. Vitetta ES. Immunotoxins: new therapeutic reagents for autoimmunity, cancer, and aids. J Clin Immunol 1990; 10: 15s-18s.
3. Rosenblum MG et al. A specific and potent immunotoxin composed of antibody ZME-018 and the plant toxin gelonin. Mol Biother 1991 3 6-13
4. Sivam G et al Immunotoxins to a human melanoma-associated antigen: comparison of gelonin with ricin and other A chain conjugates Cancer Res 1987; 47: 3169-3173.
5. Stirpe F, Olsnes SE, Pihl A. Gelonin, a new inhibitor of protein synthesis, nontoxic to intact cells. Isolation, characterization, and preparation of cytotoxic complexes with concanavalin A. J Biol Chem 1980; 255: 6947-6953.
6. Barbieri L, Stirpe F. Ribosome-inactivating proteins from plants: properties and possible uses. Cancer Survevs 1982; 1: 489-520.
7. Rosenblum MG et al. Amino acid sequence analysis, gene construction, cloning, and expression of gelonin, a toxin derived from Gelonium multiflorum. J. Interferon Cytokine Res 1995; 15: 547-555.
8. Brigotti N et al. Effects of alpha-sarcin and ribosome inactivating proteins on the interaction of elongation factors with ribosomes. Biochem J 1989; 257: 723-727.
9. Raso V, Watkins SC, Slayter H, Fehrmann C. Intracellular pathways of ricin A chain cytotoxins. Ann NY Acad Sci 1987; 507: 172-186.
10. Blakey DC, Thorpe PE. An overview of therapy with immunotoxins containing ricin or its A-chain: Antibod Immunoconj Radiopharm 1988; 1: 1-16
11. Blattler WA, Lambert JM, Goldmacher VD. Realizing the full potential of immunotoxins. Cancer Cells 1989; 1: 50-55.
12. McGraw KJ, Rosenblum MG, Cheung L, Scheinberg DA. Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias. Cancer Immunol Immunother 1994; 39: 367-374.
13. Griffin D et al. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leukemia Res 1984; 8: 521-534.
14. Robertson MJ et al. Human bone marrow depleted of CD33-positive cells mediated delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia. Blood 1992; 79: 2229-2236.
15. Scheinberg DA et al. Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia. Leukemia 1989; 3: 440-445.
16. Tanimoto M et al. Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195. Leukemia 1989; 3: 339-348.
17. Bernstein ID et al. Treatment of acute myeloid leukemia cells in vitro with monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed. J Clin Invest 1987; 79: 1153-1159.
18. + human marrow cells to establish in vitro hematopoiesis in long-term marrow culture. Exp Hematol 1992; 20: 442-448.
19. Caron PC et al. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies Cancer Res 1992; 52: 6761-6767.
20. Brown PS Jr et al Anti-Tac-H, a humanized antibody to the interleukin-2 receptor, prolongs primate cardiac allograft survival. Proc Natl Acad Sci USA 1991; 88: 2663-2667.
21. Co MS et al. Chimeric and humanized antibodies with specificity for the CD33 antigen. J Immunol 1992; 148: 1149-1154.
22. Caron PC et al. A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogencity. Blood 1994; 83: 1760-1768.
23. Scheinberg DA et al. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J Clin Oncol 1991; 9: 478-490.
24. Andrews RG, Torok-Storb B, Bernstein ID. Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies. Blood 1983; 62: 124-132.
25. Schwartz MA et al. Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory meyloid leukemias. J Clin Oncol 1993; 11: 294-303.
26. Xu Y, Scheinberg DA. Elimination of human leukemia by monoclonal antibodies in an athymic nude mouse leukemia model. Clin Cancer Res 1995; 1: 1179-1187.
27. Roy DC et al. Anti-MY9-blocked ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells. Blood 1991; 77: 2404-2412.
28. Preijers FWMB et al. Autologous transplantation of bone marrow purged in vitro with anti-CD7-(WT1-) ricin A immunotoxin in T-cell lymphoblastic leukemia and lymphoma. Blood 1989; 74: 1152-1158.
29. + human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide. Blood 1992; 79: 3116-3129.
30. Ghetie MA et al. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin. Blood 1992; 80: 2315-2320.
31. Jansen B et al. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin a-chain immunotoxin DA7. Cancer Res 1992; 52: 1314-1321.
32. Jansen B, Uckun FM, Jaszcz WB, Kersey JH. Establishment of a human t(4;11) leukemia in severe combined immunodeficient mice and successful treatment using anti-CD 19 (B43)-pokeweed antiviral protein immunotoxin. Cancer Res 1992; 52: 406-412.
33. Grossbard ML et al. Serotherapy of B-cell neoplasms with anti-B-4-blocked ricin: a phase I trial of daily bolus infusion. Blood 1992; 79: 576-585.
34. French RR et al. Delivery of the ribosome-inactivating protein, gelonin, to lymphoma cells via CD22 and CD38 using bispecific antibodies. Br J Cancer 1995; 71: 986-994.
35. French RR et al. Treatment of B-cell lymphomas with combination of bispecific antibodies and saporin. Lancet 1995; 346: 223-224.
36. Trowbridge IS, Domingo DL. Prospects for the clinical use of cytotoxic monoclonal antibody conjugates in the treatment of cancer. Cancer Surv 1982; 1: 544-556.
37. Jurcic JG, Scheinberg DA. Monoclonal antibody therapy of myeloid leukemias. Princ Pract Oncol 1995; 9: 1-12.